Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Cagrilintide

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

Novo Nordisk · Phase 1 · Completed · Enrollment 178

NCT06719011

ArmPopulationDoseWeeksEstimandWeight change
Part A: NNC0174-1213 (SD1-SD5)Obesity or overweightn/rn/rn/rn/r
Part A: Cagrilintide (SDA and SDB)Obesity or overweightn/rn/rn/rn/r
Part A: PlaceboObesity or overweightn/rn/rn/rn/r
Part B: NNC0174-1213 (MD1-MD5)Obesity or overweightn/rn/rn/rn/r
Part B: Cagrilintide (MDA)Obesity or overweightn/rn/rn/rn/r
Part B: PlaceboObesity or overweightn/rn/rn/rn/r